Perioperative management of cardiac ischemia: Difference between revisions

From IDWiki
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations")
No edit summary
 
Line 1: Line 1:
== Background ==
* Highest risk period for MI is post-op day 3


== Epidemiology ==
===Epidemiology===


* Represents 1-6% of cardiac events
*Represents 1-6% of cardiac events


== Etiology ==
===Etiology===


* Bleeding (35%)
*Bleeding (35%)
* Cardiac cause (44%), including MI, AV block, arrhythmias
*Cardiac cause (44%), including MI, AV block, arrhythmias
* Other (21%), including PE, anaphylaxis, and hypoxemia
*Other (21%), including PE, anaphylaxis, and hypoxemia


== Pathophysiology ==
===Pathophysiology===


* Thrombosis
*Thrombosis
* Catecholamine surges from stress state
*Catecholamine surges from stress state
* Obstruction
*Obstruction
* Infection or inflammation
*Infection or inflammation
* Increased demand, from tachycardia, fever, hypotension, anemia, and hypoxemia
*Increased demand, from tachycardia, fever, hypotension, anemia, and hypoxemia


== Clinical Manifestations ==
==Clinical Manifestations==


*Highest risk period for MI is post-op day 3
* Myocardial infarction after non-cardiac surgery (MINS)
*[[Myocardial infarction after non-cardiac surgery]] (MINS)
* STEMI is rare
*[[STEMI]] is rare


== Diagnosis ==
==Diagnosis==


* Increased troponin with typical pattern
*Increased troponin with typical pattern
* Signs of ischemia, including Q waves on ECG or wall motion abnormalities on echocardiography
*Signs of ischemia, including Q waves on ECG or wall motion abnormalities on echocardiography


== Management ==
==Management==


* Treat underlying cause
*Treat underlying cause
* Add ASA and beta blocker, consider ACE inhibitor or nitrates
*Add ASA and beta blocker, consider ACE inhibitor or nitrates


== Preoperative assessment ==
==Preoperative assessment==


* If surgery is emergent, proceed to OR
*If surgery is emergent, proceed to OR
* If not emergent, then rule out ACS and treat this first
*If not emergent, then rule out ACS and treat this first
* If not having ACS, then risk stratify with AHA class or RCRI or NSQuIP
*If not having ACS, then risk stratify with AHA class or RCRI or NSQuIP
* Elective surgery should be delayed for:
*Elective surgery should be delayed for:
** Anticoagulation/antiplatelets
**Anticoagulation/antiplatelets
** Electrolyte abnormalities
**Electrolyte abnormalities
** Infection, especially pneumonia
**Infection, especially pneumonia
** Obstructions in the vasculature (ACS or PE within the past month)
**Obstructions in the vasculature (ACS or PE within the past month)
** Unstable vitals
**Unstable vitals


== Prognosis ==
==Prognosis==


* 15-25% in-hospital mortality
*15-25% in-hospital mortality
* Outcomes are related to peak troponin (per VISION study)
*Outcomes are related to peak troponin (per VISION study)


[[Category:Perioperative medicine]]
[[Category:Perioperative medicine]]

Latest revision as of 12:19, 2 August 2020

Background

Epidemiology

  • Represents 1-6% of cardiac events

Etiology

  • Bleeding (35%)
  • Cardiac cause (44%), including MI, AV block, arrhythmias
  • Other (21%), including PE, anaphylaxis, and hypoxemia

Pathophysiology

  • Thrombosis
  • Catecholamine surges from stress state
  • Obstruction
  • Infection or inflammation
  • Increased demand, from tachycardia, fever, hypotension, anemia, and hypoxemia

Clinical Manifestations

Diagnosis

  • Increased troponin with typical pattern
  • Signs of ischemia, including Q waves on ECG or wall motion abnormalities on echocardiography

Management

  • Treat underlying cause
  • Add ASA and beta blocker, consider ACE inhibitor or nitrates

Preoperative assessment

  • If surgery is emergent, proceed to OR
  • If not emergent, then rule out ACS and treat this first
  • If not having ACS, then risk stratify with AHA class or RCRI or NSQuIP
  • Elective surgery should be delayed for:
    • Anticoagulation/antiplatelets
    • Electrolyte abnormalities
    • Infection, especially pneumonia
    • Obstructions in the vasculature (ACS or PE within the past month)
    • Unstable vitals

Prognosis

  • 15-25% in-hospital mortality
  • Outcomes are related to peak troponin (per VISION study)